Primary and secondary lung malignancies treated with percutaneous radiofrequency ablation: Evaluation with follow-up helical CT

被引:59
作者
Jin, GY
Lee, JM
Lee, YC
Han, YM
Lim, YS
机构
[1] Seoul Natl Univ Hosp, Dept Radiol, Seoul 110744, South Korea
[2] Chonbuk Natl Univ Hosp, Dept Diagnost Radiol, Chonbuk 561712, South Korea
[3] Chonbuk Natl Univ Hosp, Dept Internal Med, Chonbuk 561712, South Korea
关键词
D O I
10.2214/ajr.183.4.1831013
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];
摘要
OBJECTIVE. We sought to describe the appearance of primary and secondary lung malignancies treated with radiofrequency ablation on follow-up helical CT and to identify the important CT findings for evaluating therapeutic efficacy and response on follow-up CT. MATERIALS AND METHODS. Among the 21 patients in our study population, 17 had lung cancer and four had metastatic nodules. All patients underwent follow-up helical CT immediately after undergoing percutancous radiofrequency ablation, 1 month later, and then every 3 months. Two reviewers interpreted the CT findings and reached a consensus opinion. Patients were divided into two groups on the basis of the posttreatment contrast-enhanced CT findings-those with a complete ablation and those with a partial ablation. The serial changes in the enhancement pattern, size, peripheral ground-glass opacities, and other findings in the treated area in the two groups were assessed on follow-up CT. RESULTS. In the complete ablation group (n = 9 patients), the ablated lesions were completely without contrast enhancement on follow-up CT, and the mean percentage of decrease in the size of the ablated lesions at 3, 6, 9, 12, and 15 months was 5.7%, 11.4%, 14.3%, 40%, and 40%, respectively, compared with the lesion size on the follow-up CT scans obtained immediately after treatment. In the partial ablation group (n = 12 patients), the ablated lesions had various degrees of enhancement, and the mean percentage of ablated lesion size gradually increased after the 6-month follow-up CT examination. Enveloped ground-glass opacity surrounding tumor was seen in five (23.8%) of 21 lesions on the immediate follow-up CT scans. CONCLUSION. Of the CT findings of lung malignancy after radiofrequency ablation therapy, the enhancement pattern and the size of the change in the ablated lesion are the most important factors for deten-nining whether a complete ablation has been achieved.
引用
收藏
页码:1013 / 1020
页数:8
相关论文
共 36 条
[1]
Feasibility and value of video-assisted thoracoscopic surgery wedge excision of small pulmonary nodules in patients with malignancy [J].
Burdine, J ;
Joyce, LD ;
Plunkett, MB ;
Inampudi, S ;
Kaye, MG ;
Dunn, DH .
CHEST, 2002, 122 (04) :1467-1470
[2]
Multiphase helical CT findings after percutaneous ablation procedures for hepatocellular carcinoma [J].
Catalano, O ;
Esposito, M ;
Nunziata, A ;
Siani, A .
ABDOMINAL IMAGING, 2000, 25 (06) :607-614
[3]
Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies - Results in 123 patients [J].
Curley, SA ;
Izzo, F ;
Delrio, P ;
Ellis, LM ;
Granchi, J ;
Vallone, P ;
Fiore, F ;
Pignata, S ;
Daniele, B ;
Cremona, F .
ANNALS OF SURGERY, 1999, 230 (01) :1-8
[4]
Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up [J].
Dromain, C ;
de Baere, T ;
Elias, D ;
Kuoch, V ;
Ducreux, M ;
Boige, V ;
Petrow, P ;
Roche, A ;
Sigal, R .
RADIOLOGY, 2002, 223 (01) :255-262
[5]
Image-guided radiofrequency tumor ablation: Challenges and opportunities - Part II [J].
Dupuy, DE ;
Goldberg, SN .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (10) :1135-1148
[6]
Percutaneous radiofrequency ablation of malignancies in the lung [J].
Dupuy, DE ;
Zagoria, RJ ;
Akerley, W ;
Mayo-Smith, WW ;
Kavanagh, PV ;
Safran, H .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2000, 174 (01) :57-59
[7]
Clinical applications of radio-frequency tumor ablation in the thorax [J].
Dupuy, DE ;
Mayo-Smith, WW ;
Abbott, GF ;
DiPetrillo, T .
RADIOGRAPHICS, 2002, 22 :S259-S269
[8]
Fedorov V D, 2002, Khirurgiia (Mosk), P4
[9]
Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO
[10]
2-9